期刊
PAPILLOMAVIRUS RESEARCH
卷 7, 期 -, 页码 52-61出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.pvr.2019.01.002
关键词
Adolescents; Clinical trials; Men who have sex with men; Vaccine; Human papillomavirus; HIV
类别
资金
- AIDS Malignancies Consortium (AMC) from the National Cancer Institute [UM1CA121974]
- Adolescent Trials Network for HIV/AIDS Interventions (ATN) from the National Institutes of Health through the National Institute of Child Health and Human Development [U01 HD 040533, U01 HD 040474]
- National Institutes on Drug Abuse and Mental Health
The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18-26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants' mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR= 2.67, 95% CI =1.11-6.42), current smoking (yes vs. no, OR = 2.37, 95% CI =1.03-5.48), and number of recent receptive anal sex partners (2 + vs. 0, OR = 3.47, 95% CI =1.16-10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据